Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID,European Journal of Heart Failure

当前位置： X-MOL 学术 › Eur. J. Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2024-06-19 , DOI: 10.1002/ejhf.3348
Nina Nouhravesh _{1,

2} , Jyotsna Garg ₁ , Frank W. Rockhold ₁ , Carmine G. De Pasquale ₃ , Eileen O'Meara ₄ , Gregory D. Lewis ₅ , Javed Butler ₆ , Josephine Harrington ₁ , Justin A. Ezekowitz ₇ , Piotr Ponikowski ₈ , Richard W. Troughton ₉ , Yee Weng Wong ₁₀ , Nicole Blackman ₁₁ , Syed Numan ₁₁ , Robert Adamczyk ₁₁ , Adrian F. Hernandez ₁ , Robert J. Mentz ₁

Affiliation

Duke Clinical Research Institute Durham NC USA
Department of Cardiology, Herlev‐Gentofte University Hospital Copenhagen Denmark
Flinders Medical Centre Adelaide SA Australia
Montreal Heart Institute and Université de Montréal Quebec Canada
Division of Cardiology Massachusetts General Hospital Boston MA USA
Department of Medicine University of Mississippi Jackson MS USA
Canadian VIGOUR Centre, University of Alberta Edmonton AB Canada
The Center for Heart Diseases University Hospital, Wroclaw Medical University Wroclaw Poland
Department of Medicine Christchurch Heart Institute, University of Otago Christchurch New Zealand
Department of Cardiovascular Medicine Mayo Clinic Rochester MN USA
American Regent Shirley NY USA

Ferric carboxymaltose (FCM) is guideline-recommended for iron deficiency (ID) in heart failure with reduced ejection fraction (HFrEF). Despite a well-established safety profile, the magnitude and clinical significance of FCM-induced hypophosphataemia in HFrEF remains unclear. This pre-specified substudy of HEART-FID evaluated serum phosphate, 1,25-dihydroxyvitamin D, and plasma parathyroid hormone (PTH) subsequent to FCM.

中文翻译：

静脉注射羧基麦芽糖铁与安慰剂治疗射血分数降低和缺铁性心力衰竭时血清磷酸盐水平随时间变化的特征：来自 HEART-FID 的一项探索性前瞻性亚研究

羧基麦芽糖铁 (FCM) 是指南推荐用于治疗射血分数降低的心力衰竭 (HFrEF) 缺铁 (ID) 的患者。尽管安全性已得到证实，但 FCM 诱导的 HFrEF 低磷酸盐血症的严重程度和临床意义仍不清楚。这项预先指定的 HEART-FID 子研究评估了 FCM 后的血清磷酸盐、1,25-二羟基维生素 D 和血浆甲状旁腺激素 (PTH)。

更新日期：2024-06-20

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>